Canaccord analyst Jason Mills raised his estimates on CryoLife following the release of its preliminary Q3 results. The analyst said its acquisitions have delivered accelerating revenue and margin expansion and he believes they have changed the company for the better. He also believes the trends will continue near-term, portending material upside to his current estimates. Mills said in light of the recent weakness, he recommends investors "go shopping" in CryoLife at current levels. Mills reiterated his Buy rating and $36 price target on CryoLife shares.